Objective-The iminosugar N-(5Ј-adamantane-1Ј-yl-methoxy)-pentyl-1-deoxynoijirimycin (AMP-DNM), an inhibitor of the enzyme glucosylceramide synthase catalyzing glycosphingolipid (GSL) biosynthesis, ameliorates diabetes and reduces liver steatosis in ob/ob mice. Because an accumulation of sphingolipids, including sphingomyelin and GSLs, has been reported in atherosclerotic lesions in animal models and in humans, the objective of this study was to determine whether AMP-DNM also exerts beneficial effects on the development of atherosclerosis.
tion and stroke and is the underlying cause of Ϸ50% of all deaths in Western countries. The use of statins as primary and secondary prevention yields a 30% decrease in cardiovascular risk. To achieve a further substantial drop in cardiovascular morbidity and mortality, new therapeutic modalities need to be developed. Targeting glycosphingolipid (GSL) synthesis may be an attractive alternative. In humans, the concentration of plasma GSLs is increased in conditions associated with atherosclerosis risk and shows a positive correlation with plasma cholesterol. 1, 2 In addition, it has been reported that GSLs accumulate in atherosclerotic lesions in humans and in apolipoprotein E-null (apoEϪ/Ϫ) mice. 3 Potential proatherogenic properties have been proposed for GSLs, mainly for lactosylceramide. Lactosylceramide was found to promote cholesterol accumulation in macrophage foam cells, inhibit cholesterol efflux, and induce monocyte adhesion to endothelial cells. 4 -6 Myriocin, an inhibitor of serine palmitoyl transferase, which catalyzes the initial step in sphingolipid biosynthesis, profoundly reduces the development of atherosclerosis in apoEϪ/Ϫ mice. 7, 8 However, its specific effect is difficult to interpret, because in addition to GSL synthesis inhibition, myriocin also modulates numerous other sphingolipids, which may have a role in the progression of the formation of atherosclerotic lesion.
The iminosugar N-(5Ј-adamantane-1Ј-yl-methoxy)-pentyl-1-deoxynoijirimycin (AMP-DNM) is a specific inhibitor of glucosylceramide (GlcCer) synthase, the enzyme catalyzing the initial step in GSL biosynthesis. 9 By decreasing the availability of GlcCer, AMP-DNM reduces the synthesis of more complex GSLs, such as gangliosides, which play a crucial role in cell membrane properties. 10 Previous work has shown that the use of the iminosugar improves glucose tolerance, reduces hepatic steatosis, and enhances insulin responsiveness in rodent models for type 2 diabetes. 11, 12 In lean mice, AMP-DNM treatment led to a decrease of plasma lipids and to a stimulation of reverse cholesterol transport that was illustrated by an increase of biliary lipid secretion and an increase of fecal sterol excretion. 13 Furthermore, this compound was shown to convey a potent antiinflammatory effect. 14, 15 On the basis of all these observations, we postulated that AMP-DNM might also show beneficial effects on cardiovascular disease. Therefore, the aim of this study was to evaluate the effect of AMP-DNM on the progression of atherosclerosis.
Materials and Methods

Materials
AMP-DNM was synthesized as previously described. 16, 17 All solvents and reagents used were of analytic grade.
Mice and Diets
APOE*3 Leiden transgenic mice 18 were maintained on a C57Bl/6 homogeneous background and housed at the Institute Animal Core Facility in a temperature-and humidity-controlled room with a 12-hour light/dark cycle. Studies were performed using female APOE*3 Leiden mice (8 to 12 weeks old) fed for 18 weeks with a high-cholesterol diet (1% cholesterol, 15% fatty acids; Arie Blok, Woerden, the Netherlands) supplemented with 0, 0.3, or 0.6 g of AMP-DNM ⅐ kg diet Ϫ1 to obtain a calculated dose of 50 or 100 mg of AMP-DNM ⅐ kg body weight (bw) Ϫ1 ⅐ day Ϫ1 , respectively. When female low-density lipoprotein receptor (LDLRϪ/Ϫ) mice were used, the diet contained 0.25% cholesterol for a period of 12 weeks. Experiments were performed with the approval of the Ethical Committee for Animal Experiments.
Plasma and Tissue Sampling
Blood samples of nonfasting animals were collected via the tail vein at the time points indicated in the figures. At the end of the experiments, large blood samples were collected by abdominal aorta puncture, and plasma samples were stored at Ϫ20°C. Hearts were flushed with PBS to remove the excess of blood before fixation in formaldehyde 1% (Formal-Fixx, Thermo Electron Corporation, Pittsburgh, Pa.) for 24 hours and storage at Ϫ80°C embedded in tissue medium (Tissue-Tek O.C.T., Sakura, Zoeterwoude, the Netherlands). Other tissues were snap frozen in liquid N 2 and stored at Ϫ80°C.
Characterization of Atherosclerotic Lesions
Frozen sections from the aortic sinus were prepared according to Paigen et al. 19 Surface lesion area was measured after Oil Red O staining by computer-assisted image quantification with Leica QWin software (Leica Microsystems, Wetzlar, Germany). Images were captured with a Leica DFC 420 video camera. At least 5 sections per mouse were examined for each staining.
Bile and Feces Sampling
Twenty-four hours of feces were collected from cages during the last day of the treatment. Mice were kept in their original cages to avoid stressful procedures. Feces were freeze-dried, weighed, and ground before storage at Ϫ20°C. Cannulation of the gall bladder and bile collection were performed as described previously. 20 After cannulation, bile was collected for 15 minutes, and bile samples were immediately frozen and stored at Ϫ20°C. Bile flow was determined gravimetrically, assuming a density of 1 g ⅐ mL Ϫ1 for bile.
Measurement of Intestinal Cholesterol Absorption
Intestinal cholesterol absorption was determined by the fecal dual-isotope ratio method 21 on mice fed for 6 weeks with the high-cholesterol diet (see above) supplemented without or with AMP-DNM. Mice (nϭ5 per group) were given an intragastric bolus of 150 L of olive oil containing 1 Ci of [ 14 C]cholesterol (Amersham Biosciences) and 2 Ci of [ 3 H]sitostanol (American Radiolabeled Chemicals, St. Louis, Mo.) by gavage. Mice were housed with 2 to 3 animals per cage. Total feces per cage were collected for 3 days, dried, and ground before extraction as described below. The ratios of the 2 radiolabels in the fecal extracts and in the dosing mixture were used to calculate the percentage of cholesterol absorption.
Analytic Procedures
Ceramide (Cer) and GlcCer were determined in liver and plasma samples after lipids extraction according to Folch et al 22 by highperformance liquid chromatography analysis of orthophtaldehydeconjugated lipids according to a procedure described previously. 11 Fecal neutral sterols were extracted from the feces and measured by gas chromatography. 23 Biliary cholesterol, bile salt, and phospholipids from bile were measured by fluorescent methods as described previously. 24 Cholesterol and triglycerides in plasma were determined using colorimetric enzymatic kits from Biolabo (Maizy, France). Plasma cholesterol concentrations in the main lipoprotein classes were determined in a pool of plasma of each group (5 mice) separated by high-performance gel filtration chromatography as described before. 25 
Statistical Analysis
Values presented in the figures represent meanϮSEM. Statistical significance between control and treated groups was determined by ANOVA (*PϽ0.05; **PϽ0.01).
Results
AMP-DNM Treatment Inhibits Atherosclerosis and Ameliorates Hyperlipidemia in APOE*3 Leiden Mice
To investigate the effect of AMP-DNM on lesion formation, APOE*3 Leiden mice were treated for 18 weeks with a high-cholesterol diet (1% weight/weight) supplemented with AMP-DNM to obtain doses of 0, 50, and 100 mg of AMP-DNM ⅐ kg bw Ϫ1 ⅐ day Ϫ1 . A repeated dose of 100 mg ⅐ kg bw Ϫ1 ⅐ day Ϫ1 of AMP-DNM is well tolerated and does not exert liver toxicity in mice. 12 In the APOE*3 Leiden mice, the drug did decrease food consumption from (2.4Ϯ0.3 g of diet ⅐ mouse Ϫ1 ⅐ day Ϫ1 at 0 mg of AMP-DNM versus 2.2Ϯ0.3 g of diet at 50 mg to 2.0Ϯ0.3 g of diet at 100 mg) (Supplemental Figure IA , available online at http://atvb.ahajournals.org). At the end of the treatment, the weight of the 2 treated groups was significantly lower than that of the control group (24.1Ϯ0.6 g at 0 mg of AMP-DNM versus 21.3Ϯ0.3 g at 50 mg versus 18.9Ϯ 0.2 g at 100 mg) (Supplemental Figure IB) . Quantification of the lesions was performed after staining of the lipid deposits in the aortic sinus with Oil Red O ( Figure 1A and 1B). AMP-DNM treatment had a spectacular inhibitory effect on the development of atherosclerosis in this model. Mice receiving the dose of 50 mg of AMP-DNM showed a reduction of 86% in the amount of lesions compared to control animals. At 100 mg of AMP-DNM, no lesions were detectable in the aortic sinus of the mice.
To investigate the mechanism by which AMP-DNM limited atherogenesis, we first studied the effects of the iminosugar on plasma lipids. AMP-DNM dosedependently lowered plasma cholesterol ( Figure 1C ) as well as triglyceride concentrations ( Figure 1D ). This effect of AMP-DNM was observed from 6 weeks of administration and was stable over time, and was reflected in an improved lipoprotein profile, that is, a reduction of cholesterol in the very low density lipoprotein/low-density lipoprotein fraction ( Figure 1E ).
The Table depicts the effect of AMP-DNM treatment on plasma GSL content. The high-cholesterol diet without AMP-DNM induced a 10-fold increase of plasma GlcCer and a 3-fold increase of Cer. At the end of the experimental period, the mice treated with AMP-DNM showed a dosedependent reduction of the amount of GlcCer and a concomitant reduction of the amount of Cer (Table) . The amount of sphingomyelin determined in a pool of plasma also decreased at the end of the treatment: 68% and 83% of reduction with 50 and 100 mg of AMP-DNM, respectively (data not shown).
AMP-DNM Treatment Lowers Lipids in the Liver of APOE*3 Leiden Mice
Next, we focused on the effect of AMP-DNM on hepatic lipid metabolism. As expected, by inhibiting GlcCer synthase, AMP-DNM dose-dependently lowered the amount of hepatic GlcCer without a change in the amount of Cer (Table) . The cholesterol and triglyceride contents were also decreased significantly in the liver of treated animals. Cholesterol decreased in a dose-dependent manner (Figure 2A ), whereas the reduction in triglycerides was similar for the 2 doses of AMP-DNM ( Figure 2B ). No effect on hepatic choline-based phospholipids was observed ( Figure 2C) .
As a consequence of lowered hepatic cholesterol levels, 26 expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase (5.1-fold) and one of its main regulators, SREBP-2 (2-fold), were increased. In accordance, the expression of LXR, ABCA1, ABCG5, and ABCG8 were decreased, whereas the expression of the very low density lipoprotein receptor and the LDLR were upregulated (Supplemental Figure IIA ).
AMP-DNM Treatment Increases Cholesterol Output in APOE*3 Leiden Mice
Because AMP-DNM treatment strongly decreased cholesterol in plasma and in livers of the treated animals, we hypothesized that AMP-DNM may have increased biliary lipid secretion and total sterol output. At the end of the treatment period, we therefore collected hepatic bile for 15 minutes. AMP-DNM treatment induced an increase of cholesterol secretion from 5.0Ϯ0.3 nmol ⅐ min Ϫ1 ⅐ 100 g bw Ϫ1 at 0 mg of AMP-DNM to 8.8Ϯ0.6 at 100 mg of AMP-DNM ( Figure 3A) , and bile salt ( Figure 3B ), phospholipid secretion ( Figure 3C ), and bile flow ( Figure 3D ) increased in a similar fashion. Interestingly, despite the high load of cholesterol in the diet, the secretion of fecal neutral sterol increased from 182 mol ⅐ 24 hour Ϫ1 ⅐ 100 g bw Ϫ1 in the control group to 232 mol ⅐ 24 hour Ϫ1 ⅐ 100 g bw Ϫ1 with AMP-DNM treat- Data are expressed as meanϮSEM of 5 mice. Pretreatment values were determined in 3 different pools of plasma collected before the start of the diet. *PϽ0.01. ment ( Figure 4A ). This increase was not accompanied by a decrease of cholesterol uptake in the intestine, as determined with the fecal dual-isotope ratio method ( Figure 4B ).
AMP-DNM Treatment Strongly Affects Atherosclerosis Development in LDLR؊/؊ Mice
To confirm the effect of AMP-DNM on atherosclerotic lesion formation, we performed a similar series of experiments in LDLRϪ/Ϫ mice. Female LDLRϪ/Ϫ mice were fed a Western-type diet (0.25% cholesterol) supplemented with the same amount of AMP-DNM to obtain the doses of 0, 50, and 100 mg of AMP-DNM ⅐ kg bw Ϫ1 ⅐ day Ϫ1 . Although both the diet-induced lesions and the diet-induced changes in plasma lipids were more significant in the LDLRϪ/Ϫ mice than in the APOE*3 Leiden mice, also in this model AMP-DNM inhibited lesion formation ( Figure 5A and 5B) . Drug treatment resulted in a reduction of plasma cholesterol ( Figure  5C ) and triglycerides ( Figure 5D ) and an amelioration in the lipoprotein profile ( Figure 5E ).
Discussion
The present study reveals that AMP-DNM, an inhibitor of GSL synthesis, dramatically reduces plasma lipid concentra- tion and atherosclerosis in APOE*3 Leiden mice. This beneficial effect of AMP-DNM was observed in APOE*3 Leiden mice and in LDLR-deficient mice. In both models, we observed a strong dose-dependent reduction of plasma cholesterol and triglycerides in combination with a dramatic reduction in the development of atherosclerotic lesions. Despite the addition of large amounts of cholesterol to the diet, in APOE*3 Leiden mice, plasma cholesterol remained close to wild type values with the dose of 100 mg of AMP-DNM, and plasma cholesterol did not rise above the threshold necessary to induce the formation of lesions. 27 It should be noted that AMP-DNM treatment of APOE*3 Leiden mice reduced food consumption and body weight particularly, at the highest dose. This effect was not observed in all mouse models. In fact, with the dose of 50 mg of AMP-DNM, despite a strong reduction of plasma cholesterol, the food consumption of the LDLRϪ/Ϫ mice remained similar to what was observed for the control group during the dosing period (Supplemental Figure IIIA) . It therefore seems very unlikely that the beneficial effects of AMP-DNM can be fully attributed to reduced food intake. Although the ability of AMP-DNM to lower plasma cholesterol levels seems pivotal in the reduction of lesion development, other effects of AMP-DNM have to be considered. The decrease of Cer and sphingomyelin in the plasma of treated animals may play an additional role in the inhibition of atherosclerosis. Leventhal et al have shown that cholesterol efflux is impaired in acid sphingomyelinase-deficient macrophages. 28 Levels of sphingomyelin in plasma correlate with the occurrence of coronary heart disease in clinical studies, 29 and Cer is involved in lipoprotein aggregation and foam cell formation. 30, 31 Reduction in both Cer and sphingomyelin is not expected to occur as the result of inhibition of GlcCer synthase. In fact, the ratio of cholesterol to Cer and the ratio of cholesterol to sphingomyelin in the plasma of the different groups did not change; they remained stable despite the extreme modulation of plasma cholesterol. This suggests that a combined elimination of excessive cholesterol, Cer, and sphingomyelin occurs with AMP-DNM treatment. The mechanism underlying this intriguing phenomenon has not yet been elucidated.
It is generally accepted that inflammatory processes play an important role in atherogenesis. AMP-DNM has been shown to convey a potent antiinflammatory effect in animal models of inflammatory bowel disease induced by chronic macrophage activation, 14 and our group also reported a beneficial effect of AMP-DNM in mouse models of the metabolic syndrome, a disease characterized by chronic low-grade inflammation. 15, 32 In the APOE*3 Leiden mice studied here, AMP-DNM treatment also decreased tumor necrosis factor-␣ and monocyte-chemoattactant protein-1 (MCP-1/CCL2) expression (Supplemental Figure II) , and therefore its antiinflammatory action may have contributed to the strong antiatherogenic effect of AMP-DNM. Similar effects were noted in LDLRϪ/Ϫ mice; we observed a reduction of 40% and 70% of plasma CCL2 levels in animals treated with 50 and 100 mg of AMP-DNM, respectively (data not shown).
An important observation in our study was the increase of bile salt and cholesterol secretion in bile of AMP-DNM treated animals. A concomitant increase in the excretion of neutral sterol in the feces was observed. It should be noted that when extrapolated to 24 hours, the stimulation of biliary cholesterol secretion could explain at most 30% of the increase in neutral fecal sterol excretion. The phenotype of animals treated with AMP-DNM resembles that of mice treated with ezetimibe, a potent inhibitor of intestinal cholesterol uptake. 33 In lean animals, ezetimibe induces a 6-fold increase of neutral sterol in the feces. 34 In apoEϪ/Ϫ mice, ezetimibe induces a massive reduction in plasma cholesterol and a strong inhibition of the development of atherosclerosis. 35 Thus, to determine whether AMP-DNM exerted an ezetimibe-like effect, we used the fecal dual-isotope ratio method to determine the rate of cholesterol absorption. No effect on intestinal cholesterol uptake after treatment with AMP-DNM was found. In fact, the absorption seemed to be slightly increased with the dose of 100 mg of AMP-DNM. In addition the expression of NPC1L1, the main protein respon- sible for cholesterol uptake in the intestine, 36 was not modulated by the inhibitor (Supplemental Figure IIB) .
Because neither inhibition of cholesterol uptake in the intestine and increase in biliary secretion of cholesterol could account for the excess in fecal sterol excretion observed with AMP-DNM, it may have been caused by an increase in transintestinal cholesterol excretion. 37 As yet, individual proteins involved in transintestinal cholesterol excretion have not been identified. The 2 half transporters ABCG5 and ABCG8 are known to be involved in cholesterol efflux from the hepatocyte to the biliary lumen, as well as in cholesterol efflux from the enterocyte to the intestinal lumen. AMP-DNM treatment did not increase expression of these transporters in the intestine or liver. It remains uncertain at present whether ABCG5 and ABCG8 are involved in the AMP-DNM induced cholesterol excretion.
The results of our study may suggest the use of GlcCer synthase inhibitors for prevention or treatment of atherosclerosis. Pharmacological lowering of GSLs by inhibition of the GlcCer synthase is a valid therapeutic approach. A compound structurally related to AMP-DNM and also an inhibitor of the GlcCer synthase, Zavesca (1,5-(butylimino)-1,5-dideoxy-Dglucitol), is already registered for treatment of Gaucher disease. 38 In addition, another well-tolerated inhibitor of GSLs biosynthesis (Genz-112638) is presently being developed as oral therapy for Gaucher disease. 39 Our investigation indicates that additional studies are warranted regarding the use of GSL biosynthesis inhibitors for cardioprotective therapy.
In conclusion, our study points to the close association of the metabolism of GSLs, lipoprotein metabolism, and atherogenesis. We clearly demonstrate that AMP-DNM, by inhibiting the biosynthesis of GSLs, profoundly lowers plasma lipids by promoting reverse cholesterol transport and bile cholesterol secretion, and it most likely stimulates transintestinal cholesterol excretion. AMP-DNM thereby protects against atherosclerosis development in mouse models closely related to human pathology.
